

Fund Information

Sector	IA Healthcare
Asset Class	Equity
Launch Date	15-Dec-2020
Fund Size	£28.1m / \$37.1m (23-Aug-2024)
Fund Manager	Julia Angeles
	Marina Record
	Rose Nguyen

How does FE fundinfo rate this fund?

FE fundinfo Crown Rating Risk Score 189

Investment Details

Initial Charge	0.00%
Annual Charges	0.50%
Note to charges	n/a
Minimum Initial Investment	£ 100,000
Minimum Additional Investment	n/a
Dividend Policy	Jun 30 (Final)
Prices	
Unit Type	ACC
Mid	57.80(GBX)
Price Date	23 Aug 2024
Yield	0.00

Codes


Citicode	T2PD
SEDOL	BMVLY03
ISIN	GB00BMVLY038



What is the Fund's objective?

The Fund aims to outperform (after deduction of costs) the MSCI AC World Index, as stated in sterling, by at least 2.5% per annum over rolling five-year periods.

Cumulative Performance



	3m	6m	1yr	3yrs	5yrs
Baillie Gifford Health Innovation B Acc	-2.0	-2.8	-5.4	-47.5	n/a
IA Healthcare	+4.3	+3.2	+12.3	+3.1	+42.5
Rank within sector	21/21	19 / 21	19/19	18 / 18	n/a
Quartile	4	4	4	4	n/a



Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance. it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise. www.trustnet.com

Baillie Gifford Health Innovation B Acc

Discrete Performance 20.0% 15.0% 10.0% 5.0% 0.0% -5.0% -10.0% -15.0% -20.0% -25.0% -30.0% -35.0% 12-24m __/∟ 0-12m Л — 24-36m _/\ 36-48m J١ - 48-60m Data from FE Analytics

	0-12m	12m-24m	24m-36m	36m-48m	48m-60m
Baillie Gifford Health Innovation B Acc	-5.4	-19.3	-31.3	n/a	n/a
IA Healthcare	+12.3	-5.9	-2.4	+19.1	+16.0
Rank within sector	19 / 19	19/19	18 / 18	n/a	n/a
Quartile	4	4	4	n/a	n/a

All prices in Pence Sterling (GBX) unless otherwise specified. Price total return performance figures are calculated on a bid price to bid price basis (mid to mid for OEICs) with net income (dividends) reinvested. Performance figures are shown in Pound Sterling (GBP).


Contact Details

Address	Calton Square, 1 Greenside Row, Edinburgh, EH1 3AN
Telephone numbers	+44 (0) 131 275 2000 (Main Number)
Website	www.bailliegifford.com
Email	enquiries@bailliegifford.com



Asset Allocation (30 Jun 2024)

Rank	Asset Classes	%
1	United States Equities	60.90
2	Denmark Equities	21.30
3	Netherlands Equities	6.50
4	Germany Equities	5.80
5	Others Equities	4.30
6	Cash	1.20




Regional Breakdown (31 Jul 2024)


Rank	Regions	%
1	USA	54.72
2	Denmark	26.37
3	Netherlands	7.34
4	Germany	6.51
5	China	1.69
6	Cash & Cash Equivalents	1.26
7	Japan	1.18
8	UK	0.94

Sector Breakdown (31 Jul 2024)

Rank	Sectors	%
1	Biotechnology/Medical	59.98
2	Healthcare & Medical Products	22.12
3	Pharmaceuticals	9.06
4	Health Care	7.59
5	Money Market	1.26



Powered by data from FE fundinfo



Powered by data from FE fundinfo

Top Holdings (31 Jul 2024)

Rank	Largest Holdings	%
1	argenx	7.34
2	Moderna	6.83



Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance. it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise. www.trustnet.com

Baillie Gifford Health Innovation B Acc

Rank	Largest Holdings	%
3	Alnylam Pharmaceuticals	6.33
4	Ambu	5.44
5	Genmab	5.31
6	ALK-Abello	5.09
7	Novo Nordisk	3.97
8	Sartorius Group	3.74
9	Zealand Pharma	3.56
10	ResMed	3.53

